Navigation Links
Landauer, Inc. Reports Fiscal 2012 Fourth Quarter And Year End Results
Date:12/10/2012

GLENWOOD, Ill., Dec. 10, 2012 /PRNewswire/ -- Landauer, Inc. (NYSE: LDR), a recognized leader in personal and environmental radiation measurement and monitoring, outsourced medical physics services and high quality medical consumable accessories, today reported financial results for its fiscal 2012 fourth quarter and year ended September 30, 2012.

Fiscal 2012 Highlights

  • Revenue grew 26.5 percent to $152.4 million, compared to fiscal year 2011.
  • Gross profit grew 19.3 percent to $87.0 million on increased revenue and improved business mix.
  • Operating income of $28.2 million includes $12.3 million of non-recurring acquisition and reorganization ($4.3 million), IT platform enhancement ($2.2 million) expense, non-cash stock based compensation ($2.4 million) and asset abandonments ($3.4 million) expenses.
  • Net income of $19.3 million, or $2.03 per diluted share, included $0.94 per diluted share of acquisition and reorganization, asset abandonment charges, IT platform enhancement, and non-cash stock based compensation expenses.
  • Adjusted EBITDA of $54.2 million increased 11.9 percent from fiscal 2011.
  • Fiscal 2012 Adjusted Free Cash Flow was $38.7 million, a 26.6 percent increase from fiscal 2011.
  • Company successfully executed the launch and operation of IT platform enhancement.
  • Company issues Fiscal 2013 guidance.
  • "Fiscal 2012 was an important year for the Company as we advanced several long-term strategic initiatives," said Bill Saxelby, President and CEO of Landauer. "We began the fiscal year with the  acquisition of IZI Medical Products, added experienced new talent to our team and ended the fiscal year with the successful launch and implementation of our IT systems initiative during the fiscal fourth quarter."

    "Against a backdrop of ongoing global economic and political uncertainty, w
    '/>"/>

    SOURCE Landauer, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

    Related medicine technology :

    1. Landauer, Inc. Reports Fiscal 2012 Second Quarter Results
    2. Landauer, Inc. Appoints Peter Cempellin To President Of Landauer Radiation Measurement
    3. Landauer, Inc. Appoints Ronald Zilkowski To Vice President, Corporate Controller And Chief Accounting Officer
    4. Landauer, Inc. Sets Date And Time For Announcement Of Fiscal Fourth Quarter And Full Year 2012 Results
    5. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    6. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    7. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
    8. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
    9. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
    10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
    11. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2014)... -- Amgen (NASDAQ: AMGN ) today announced ... results include: , Total revenues increased 11 percent ... driven by strong performance across the portfolio, particularly Enbrel ... (denosumab) and XGEVA ® (denosumab). , ... higher revenues and a significant increase in the profitability ...
    (Date:7/29/2014)... , July 29, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... participating in two healthcare conferences during the third quarter, ... Morgan Stanley Global Healthcare 2014 Conference.  Alexza,s corporate presentation ... The details on each event are below: ... 11, 2014 in Boston , MA.  ...
    (Date:7/29/2014)... Md. , July 29, 2014  Synthetic Biologics, ... biologic and drug candidates targeting specific pathogens that cause ... of the unusual market activity in the Company,s stock, ... in accordance with its usual practice. The Company stated ... market activity. About Synthetic Biologics, Inc. ...
    Breaking Medicine Technology:Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2
    ... is little evidence to support the use of atypical ... approved purposes, even though many clinicians continue to commonly ... to a new report from the U.S. Department of ... and Quality (AHRQ). An article based on information in ...
    ... The Houston Business Journal recently announced that eCardio Diagnostics ... Fast 100, which included a distinguished list of 100 of ... eCardio was ranked No. 17 with a two-year growth ... to receive this prestigious award. "There were so ...
    Cached Medicine Technology:"Off-Label" Use of Antipsychotic Drugs for Some Conditions Not Supported By Evidence 2eCardio Among Honorees of the Houston Business Journal's Fast 100 List for Second Consecutive Year 2
    (Date:7/30/2014)... Connecticut (PRWEB) July 30, 2014 Pain ... new magnetic sports bracelet for pain relief and improved ... strength carbonized titanium embedded in a silicone core that ... also has Germanium and is embedded with scalar energy ... bracelet. , “Pain Free Living has 12 years experience ...
    (Date:7/29/2014)... July 29, 2014 Paul Mata, CEO of ... More Money in 30 Days” E-book. The e-book includes a ... to make extra cash. Examples include downloading and utilizing specific ... websites that help people monetize the assets they didn't know ... items they can find in their garage. , After ...
    (Date:7/29/2014)... 1Heart Caregiver Services’ advocacy on ... on Brain Fitness Education brings great acceptance from ... Program Director Tee Barr delivered an exceptional Brain ... and the Assisted Living section of Aegis Ventura ... Christy Rozsa and Aegis Life Neighborhood Director Christine ...
    (Date:7/29/2014)... 29, 2014 Daily Gossip indicates that ... all other disturbing symptoms that hemorrhoids commonly causes. The ... and natural medicine expert. , The author of ... the elimination of symptoms such as itching, burning, pain ... more about the H Miracle by visiting the official ...
    (Date:7/29/2014)... 2014 The One Minute Herpes Cure review ... an herbal medicine specialist. Alison Freeman wanted to show her ... , People interested in finding out more about this method ... it, as it is currently available in online format. , ... remedies and herbal medicine tips that can help them achieve ...
    Breaking Medicine News(10 mins):Health News:Superior Magnetics Released New Magnetic Sports Bracelet for Pain 2Health News:Create Indestructible Wealth Launches Innovative E-Book: “Realistic Ways to Make More Money in 30 Days” 2Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 2Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 3Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 4Health News:H Miracle Review Exposes Natural Method to Cure Hemorrhoids 2Health News:One Minute to Herpes Cure Review Reveals Simplest Herpes Treatment 2
    ... say, Montelukast, a leukotriene-receptor antagonist (leukotrienes mediate inflammation // ... reactions), decreased incidents of asthma in young children by ... ,Researchers conducted a one-year study involving 549 children ... 278 of the children received low-dose montelukast once a ...
    ... considered till now that after delivery depressions, that had plagued new ... trauma of the delivery. As a result of this belief, many ... depression. A new study that comes in the recent issue of ... ,According to Deirdre Murphy of Dundee University, who had led ...
    ... treat patients with acute traumatic brain injury, may lead to ... & Tropical Medicine. ,British researchers had studied the ... brain injury. The study was conducted to see the effect ... results showed that there seems to be an increase in ...
    ... their mothers to see if there was a link between ... life and children's antisocial behavior by age 7 , researchers ... problems with conduct and more antisocial behavior . ,Results ... birth and the likeliness of antisocial behavior in children by ...
    ... to a recent study researchers say those in the ... // an increased risk of suicidal behavior . ... and other clinical conditions were studied. Patients taking SSRIs ... taking placebo. Researchers say they found no difference ...
    ... Quetiapine, a drug used to treat agitation in patients ... say researchers based on findings of a recent study ... patients were observed . Twenty-six of the patients received ... rivastigmine (a cholinesterase inhibitor also known as Exelon), and ...
    Cached Medicine News:
    Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
    Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
    Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
    Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
    Medicine Products: